The marine natural product Scalarin inhibits the receptor for advanced glycation end products (RAGE) and autophagy in the PANC-1 and MIA PaCa-2 pancreatic cancer cell lines

Investigational New Drugs
Esther A GuzmánAmy E Wright

Abstract

Pancreatic cancer, the fourth leading cause of cancer death in the United States, has a negative prognosis because metastasis occurs before symptoms manifest. Although combination therapies are showing improvements in treatment, the survival rate for pancreatic cancer five years post diagnosis is only 8%, stressing the need for new treatments. The receptor for advanced glycation end products (RAGE) has recently emerged as a chemotherapeutic target in KRAS driven pancreatic cancers both for treatment and in chemoprevention. RAGE appears to be an important regulator of inflammatory, stress and survival pathways that lead to carcinogenesis, resistance to chemotherapy, enhanced proliferation and the high metastatic potential of pancreatic cancer. RAGE expression has been demonstrated in pancreatic cancer tumors but not in adjacent epithelial tissues. Its presence is associated with increased proliferation and metastasis. In an effort to identify novel inhibitors of RAGE among our collection of marine-derived secondary metabolites, a cell-based screening assay utilizing flow cytometry was developed. This effort led to the identification of scalarin as the active compound in a marine sponge identified as Euryspongia cf. rosea. Scalar...Continue Reading

References

Mar 29, 2003·Journal of Natural Products·Sachiko TsukamotoTomihisa Ohta
Nov 18, 2003·The Journal of Biological Chemistry·Thiruvengadam ArumugamCraig D Logsdon
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thiruvengadam ArumugamCraig D Logsdon
Sep 1, 2005·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Angelika BierhausPeter P Nawroth
Dec 21, 2006·Journal of the National Cancer Institute·Thiruvengadam ArumugamCraig D Logsdon
Mar 19, 2009·Journal of Translational Medicine·Louis J SparveroMichael T Lotze
Mar 3, 2010·Annual Review of Immunology·Gary P SimsAnthony J Coyle
Feb 15, 2011·Autophagy·Rui KangHerbert J Zeh
Feb 25, 2011·Molecules and Cells·Sun-Ho HanInhee Mook-Jung
Mar 17, 2011·Genes & Development·Shenghong YangAlec C Kimmelman
Nov 7, 2014·International Journal of Molecular Sciences·Yeon-Ju LeeJieun Yun

❮ Previous
Next ❯

Citations

Nov 6, 2018·International Journal of Molecular Sciences·Xing-Xian GuoJing Li
Sep 25, 2020·Marine Drugs·Sergey A Dyshlovoy
Nov 10, 2020·Autophagy·Jingbo LiDaolin Tang
Jan 29, 2021·Journal of Biochemical and Molecular Toxicology·C R Sruthi, K G Raghu
Aug 8, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Taitusi TaufaRobert A Keyzers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autophagy & Disease

Autophagy is an important cellular process for normal physiology and both elevated and decreased levels of autophagy are associated with disease. Here is the latest research.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms